Intech Biopharm is a leading biotechnology company specializing in the research and development of innovative treatments for lung diseases, including asthma, as well as anti-cancer therapies. Established in 2010, Intech Biopharm stands out with its unique HFA MDI (Hydrofluoroalkane Metered Dose Inhaler) technology platform, which is one of the few in the world and the only one in Taiwan. Committed to international standards, Intech Biopharm's research and control processes adhere to strict guidelines and utilize state-of-the-art testing equipment that meets European Union regulations.

With a dedicated team of professionals, strategic international collaborations, and strong marketing capabilities, Intech Biopharm focuses on patient needs and innovative research, aiming to develop high-quality products that meet international standards. Their advantages lie in their high-entry barrier technology platform, top-notch production processes, expert research team, sound financial planning, and comprehensive marketing strategies. Guided by the principles of innovation, quality, professionalism, and care, Intech Biopharm is committed to creating safer, more convenient medications and improving the overall quality of life